FDG PET Can Replace Bone Scintigraphy in Primary Staging of Malignant Lymphoma

• Published in: The Journal of nuclear medicine (1978) Vol. 40; no. 9; pp. 1407 - 1413
• Main Authors: Moog, Florian, Kotzerke, Jorg, Reske, Sven N
• Format: Journal Article
• Language: English
• Published: Reston, VA Soc Nuclear Med 01.09.1999; Society of Nuclear Medicine
• Subjects: Adolescent; Adult; Aged; Biological and medical sciences; Biopsy; Bone and Bones - diagnostic imaging; Bone Marrow - pathology; Bone Neoplasms - diagnostic imaging; Female; Fluorodeoxyglucose F18; Hematologic and hematopoietic diseases; Humans; Investigative techniques, diagnostic techniques (general aspects); Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma - diagnostic imaging; Lymphoma - pathology; Male; Medical sciences; Middle Aged; Neoplasm Staging; Osteoarticular system. Muscles; Predictive Value of Tests; Radionuclide investigations; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed; Radionuclide study; Human; Fluorine; Indication; Stage classification; Malignant hemopathy; Scintigraphy; Sensitivity; Lymphoproliferative syndrome; Medical imagery; Malignant lymphoma; Bone; Comparative study; Emission tomography
• ISSN: 0161-5505; 1535-5667

Recent studies indicated that 18F-fluorodeoxyglucose (FDG) PET may be more accurate than CT in staging nodal and extranodal malignant lymphoma. The objective of this study was to compare conventional bone scintigraphy as an established skeletal staging procedure with PET using FDG in the detection of osseous involvement in malignant lymphoma. Whole-body PET-based staging studies of 56 consecutive patients with proven Hodgkin's disease (n = 34) or non-Hodgkin's lymphoma (n = 22) were compared with the results of bone scintigraphy. Positive PET or bone scintigraphic findings were confirmed, if possible, by biopsy, MRI, CT or radiographic investigations. Of the 56 patients studied, 12 were found to have skeletal involvement on both studies (PET, 30 regions; bone scintigraphy, 20 regions). Findings were confirmed in all 12 patients. FDG PET detected an additional 12 involved regions in 5 patients. This was subsequently verified in 3 patients, although the other 2 cases remained unresolved. Conversely, bone scintigraphy revealed five abnormalities compatible with lymphoma in 5 patients. Three of these lesions were found to be erroneous; final evaluation of the remaining two findings was not possible. FDG PET is suitable for identifying osseous involvement in malignant lymphoma with a high positive predictive value and is thereby more sensitive and specific than bone scintigraphy.